Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials
Brain Sciences · 24.01.2024 · 14 (2) · 120
DOI: 10.3390/brainsci14020120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 24.01.2024. Verfasst von Adele Gaspar Lopes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rett syndrome (RTT) is a neurological disorder that mostly affects females, with a frequency of 1 in 10,000 to 20,000 live birth cases. Symptoms include stereotyped hand movements; impaired learning, language, and communication skills; sudden loss of speech; reduced lifespan; retarded growth; disturbance of sleep and breathing; seizures; autism; and gait apraxia. Pneumonia is the most common cause of death for patients with Rett syndrome, with a survival rate of 77.8% at 25 years of age. Survival into the fifth decade is typical in Rett syndrome, and the leading cause of death is cardiorespiratory compromise. Rett syndrome progression has multiple stages; however, most phenotypes are associated with the nervous system and brain. In total, 95% of Rett syndrome cases are due to mutations in the MECP2 gene, an X-linked gene that encodes for the methyl CpG binding protein, a regulator of gene expression. In this review, we summarize the recent developments in the field of Rett syndrome and therapeutics targeting MECP2.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada.
- Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
- Department of Biochemistry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
- Departments of Experimental Surgery and Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
- Ingram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 2M7, Canada.
ORCID-Profile: Adele Gaspar Lopes, Jayalakshmi Caliaperumal
Zitieren
APA
Lopes, A. G., Loganathan, S. K., & Caliaperumal, J. (2024). Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials. Brain Sciences, 14(2), 120. https://doi.org/10.3390/brainsci14020120
Vancouver
Lopes AG, Loganathan SK, Caliaperumal J. Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials. Brain Sciences. 2024;14(2):120. doi:10.3390/brainsci14020120
BibTeX
@article{Lopes2024,
author = {Lopes, Adele Gaspar and Loganathan, Sampath Kumar and Caliaperumal, Jayalakshmi},
title = {Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials},
journal = {Brain Sciences},
year = {2024},
volume = {14},
number = {2},
pages = {120},
doi = {10.3390/brainsci14020120}
}
EUVIMED